Loading
California gynaecologic oncologist who led GOG 240, the trial that made bevacizumab the first targeted drug to lengthen survival in advanced cervical cancer, and EMPOWER-Cervical 1, which did the same for the PD-1 antibody cemiplimab.
Krishnansu Tewari is a gynaecologic oncologist at the University of California, Irvine. He was first author of the 2014 New England Journal of Medicine report of GOG 240, in which adding bevacizumab to chemotherapy improved overall survival in recurrent, persistent or metastatic cervical cancer, and of the 2022 New England Journal of Medicine report of EMPOWER-Cervical 1, in which cemiplimab lengthened survival compared with chemotherapy after platinum failure.
| Title | Journal | Year |
|---|---|---|
| EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum | New England Journal of Medicine | 2022 |
| GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer | New England Journal of Medicine | 2014 |
Cemiplimab is an option for second-line cervical cancer in patients who have not had immunotherapy, though most now receive pembrolizumab first line, moving cemiplimab later or out of sequence.
Platinum-paclitaxel with bevacizumab became the first-line standard for advanced cervical cancer and remains the backbone to which pembrolizumab is added.
Shares EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum, Recurrent or metastatic cervical cancer, Cervical cancer.
Shares the tags gynaecological, trialist.
Shares the tags gynaecological, trialist.
Shares the tags gynaecological, trialist.
Shares Cervical cancer and the tags gynaecological, trialist.
Shares Cervical cancer and the tags cervical, trialist.
Shares the tags gynaecological, trialist.
Shares the tags gynaecological, trialist.